asthma and cardiovascular disease (CVD) often co-exist. when a patient has both conditions, management requires an approach that addresses the unique challenges of each condition separately, while also considering their potential interactions. however, specific guidance on the management of asthma in patients with CVD and on the management of CVD in patients with asthma is still lacking. nevertheless, health care providers need to adopt a comprehensive approach that includes both respiratory and CVD health. the management of CVD in patients with asthma requires a delicate balance between controlling respiratory symptoms and minimising potential cardiovascular (CV) risks. In the absence of specific guidelines for the management of patients with both conditions, the most prudent approach would be to follow established guidelines for each condition independently. careful selection of asthma medications is essential to avoid exacerbation of CV symptoms. In addition, optimal management of CV risk factors is essential. however, close monitoring of these patients is important as there is evidence that some asthma medications may have adverse effects on CVD and, conversely, that some CVD medications may worsen asthma symptoms. on the other hand, there is also increasing evidence of the potential beneficial effects of asthma medications on CVD and, conversely, that some CVD medications may reduce the severity of asthma symptoms. we aim to elucidate the potential risks and benefits associated with the use of asthma medications in patients with CVD, and the potential pulmonary risks and benefits for patients with asthma who are prescribed CVD medications.

Cazzola, M., Page, C.p., Hanania, N.a., Calzetta, L., Matera, M.g., Rogliani, P. (2024). Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences. DRUGS, 84(10), 1251-1273 [10.1007/s40265-024-02086-5].

Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences

Mario Cazzola;Luigino Calzetta;Maria Gabriella Matera;Paola Rogliani
2024-01-01

Abstract

asthma and cardiovascular disease (CVD) often co-exist. when a patient has both conditions, management requires an approach that addresses the unique challenges of each condition separately, while also considering their potential interactions. however, specific guidance on the management of asthma in patients with CVD and on the management of CVD in patients with asthma is still lacking. nevertheless, health care providers need to adopt a comprehensive approach that includes both respiratory and CVD health. the management of CVD in patients with asthma requires a delicate balance between controlling respiratory symptoms and minimising potential cardiovascular (CV) risks. In the absence of specific guidelines for the management of patients with both conditions, the most prudent approach would be to follow established guidelines for each condition independently. careful selection of asthma medications is essential to avoid exacerbation of CV symptoms. In addition, optimal management of CV risk factors is essential. however, close monitoring of these patients is important as there is evidence that some asthma medications may have adverse effects on CVD and, conversely, that some CVD medications may worsen asthma symptoms. on the other hand, there is also increasing evidence of the potential beneficial effects of asthma medications on CVD and, conversely, that some CVD medications may reduce the severity of asthma symptoms. we aim to elucidate the potential risks and benefits associated with the use of asthma medications in patients with CVD, and the potential pulmonary risks and benefits for patients with asthma who are prescribed CVD medications.
2024
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MEDS-07/A - Malattie dell'apparato respiratorio
English
Cazzola, M., Page, C.p., Hanania, N.a., Calzetta, L., Matera, M.g., Rogliani, P. (2024). Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences. DRUGS, 84(10), 1251-1273 [10.1007/s40265-024-02086-5].
Cazzola, M; Page, Cp; Hanania, Na; Calzetta, L; Matera, Mg; Rogliani, P
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
s40265-024-02086-5.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 4.68 MB
Formato Adobe PDF
4.68 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/391975
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact